ClinicalTrials.gg
CompletedNCT00982007Updated Feb 20, 2018Results posted

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate Tablets in Iron Deficiency Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
997
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
6th of 57
997 · median 100
Started
2009
with 5 others
Phase 3
16 of 57
none open now
Registered
7th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 6th largest by enrollment, is one of 6 that started in 2009, is one of 16 in phase 3, and was the 7th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to oral iron.

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • IDA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ to 18 years of age and able to give .
  • Diagnosis of Iron Deficiency Anemia (IDA).
  • (Hgb) ≤ to 11 g/dL.
  • Ferritin ≤ to 100 ng/mL or ≤ 300 when Transferrin Saturation (TSAT) was ≤ 30%.
  • Must demonstrate an unsatisfactory response or intolerance to oral iron.

Exclusion criteria

Exclusion Criteria:

  • Known reaction to any component of ferric carboxymaltose or ferrous sulfate.
  • Previously randomized in a clinical study of Ferric Carboxymaltose (FCM).
  • Requires dialysis for treatment of chronic kidney disease.
  • No evidence of iron deficiency.
  • Any non-viral infection.
  • or ALT at screen 1, as determined by central labs, greater than 1.5 times the .
  • Known positive hepatitis with evidence of active disease.
  • Received an drug within 30 days of screening.
  • Alcohol or drug abuse within the past 6 months.
  • Hemochromatosis or other iron storage disorders.
  • Estimated of less than 6 months or, for cancer patients, an Performance Status greater than 1.
  • Any other laboratory abnormality, medical condition, or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
  • Pregnant or sexually-active females who are of and who are not willing to use an acceptable form of .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
997 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)

    Intravenous (IV) iron

    Drug: Ferric Carboxymaltose (FCM)

  • Active comparator
    Cohort 1 (Group B) - Ferrous Sulfate

    Oral iron - Ferrous Sulfate tablets

    Drug: Ferrous Sulfate Tablets

  • Active comparator
    Cohort 2 (Group D) - IV Iron (standard of care)

    Other IV iron

    Drug: IV Iron (standard of care)

  • Experimental
    Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)

    Intravenous (IV) iron

    Drug: Ferric Carboxymaltose (FCM)

Interventions

  • A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.

  • 325 mg Ferrous Sulfate tablets taken orally three times a day

  • DrugIV Iron (standard of care)

    IV standard of care (other IV iron) per the Investigator's discretion

  • A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.

06

What researchers measure

Primary outcomes

  1. Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.

    Time frame: Day 35

07

Results

Posted Oct 18, 2013

Participant flow

Hospitals and Medical Clinics

Participant flow — Overall Study
MilestoneCohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)
Started250257253251
Completed246253253245
Not completed4406

Outcome measures

PrimaryMean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.
Time frame:
Day 35
Reported as:
Mean · g/dL
Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.
g/dLCohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)
Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.1.57 ± 1.1940.80 ± 0.7992.90 ± 1.6402.16 ± 1.252

Adverse events

Collected over 1 year and 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)—8/246 (3.3%)31/246 (12.6%)
Cohort 1 (Group B) - Ferrous Sulfate—10/253 (4%)5/253 (2%)
Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)—17/253 (6.7%)26/253 (10.3%)
Cohort 2 (Group D) - IV Iron (Standard of Care)—16/245 (6.5%)10/245 (4.1%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventCohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)
HypersensitivityImmune system disorders0/2460/2530/2533/245
MenorrhagiaReproductive system and breast disorders1/2460/2532/2532/245
AnemiaBlood and lymphatic system disorders1/2460/2532/2531/245
ColitisGastrointestinal disorders0/2460/2530/2531/245
Gastrointestinal hemorrhageGastrointestinal disorders1/2460/2530/2531/245
CholelithiasisHepatobiliary disorders0/2460/2530/2531/245
Herpes zosterInfections and infestations0/2460/2530/2531/245
Accidental overdoseInjury, poisoning and procedural complications0/2460/2530/2531/245
Carpal tunnel syndromeNervous system disorders0/2460/2530/2531/245
Transient ischemic attackNervous system disorders0/2460/2530/2531/245
Most frequent other events
Most frequent other events
EventCohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)
NauseaGastrointestinal disorders20/2465/25310/25310/245
HypophosphatemiaMetabolism and nutrition disorders11/2460/25316/2530/245

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)Total
<=18 years272314
Between 18 and 65 years209208216218851
>=65 years35383524132
Age, Continuous
Age, Continuous(years)Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)Total
Mean43.1 ± 17.1843.5 ± 17.7143.6 ± 16.8842.6 ± 15.5143.2 ± 16.63
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)Total
Female233238239231941
Male1315141456
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)Cohort 1 (Group B) - Ferrous SulfateCohort 2 (Group C) - Ferric Carboxymaltose (FCM)Cohort 2 (Group D) - IV Iron (Standard of Care)Total
United States246253253245997
08

Study locations

1 site
  • Luitpold Pharmaceuticals, Inc.
    Norristown, Pennsylvania 19403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2009
First posted
Sep 22, 2009
Start
Sep 2009
Primary completionActual
Mar 2011
CompletionActual
Aug 2011
Results first posted
Oct 18, 2013
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00982007
Responsible party
Sponsor
First posted
Sep 22, 2009
Start date
Sep 2009
Primary completion
Mar 2011
Completion
Aug 2011
Results posted
Oct 18, 2013
Last update
Feb 20, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion